XOMA Royalty (XOMA) Capital Expenditures (2010 - 2024)

XOMA Royalty (XOMA) reported Capital Expenditures of $3000.0 for Q4 2024, down 82.35% sequentially from $17000.0 in Q1 2024.

XOMA Royalty (XOMA) Capital Expenditures (2010 - 2024) Analysis & Trends

XOMA Royalty (XOMA) has 9 years of Capital Expenditures data on file, last reported at $3000.0 in Q4 2024.

For the quarter ending Q4 2024, Capital Expenditures changed N/A year-over-year to $3000.0; the trailing twelve-month figure through Dec 2024 stood at $20000.0 (changed N/A YoY), and the FY2024 full-year result was $20000.0, up 17.65% from the prior year.
Capital Expenditures eased to $3000.0 in Q4 2024, from $17000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $17000.0 in Q1 2024 to a low of $3000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	XOMA Royalty	478.42 Mn	412.34 Mn	-	-

Download Data